[{"orgOrder":0,"company":"Royalsense","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Pantoprazole Sodium","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Royalsense","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Royalsense \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Royalsense \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Domperidone

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : OPENTOP D (pantoprazole Sodium and domperidone) Delayed-Release tablets are indicated for short-term treatment of Erosive Esophagitis Associated with GERD.

                          Brand Name : Opentop D

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 28, 2024

                          Lead Product(s) : Pantoprazole Sodium,Domperidone

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank